April 3 (Reuters) - TherapeuticsMD Inc
* TherapeuticsMD presents positive phase 3 data in two presentations for TX-001HR at ENDO 2017
* TherapeuticsMD Inc - Results of replenish trial show positive safety and efficacy of TX-001HR
* TherapeuticsMD - Trial achieved statistically significant, clinically meaningful reduction in both frequency and severity of hot flashes compared to placebo Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.